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site occurred in 3 (3%) of patients in the NTC group, all requiring
catheter removal, and in 15 (16%) of patients in the TC group,
with 8 requiring catheter removal (bleeding was controlled in the
remaining patients using local pressure at the catheter entrance
site). The use of dual-lumen, tunneled, cuffed catheters for patients
with AL amyloidosis undergoing AuSCT appears to reduce the
incidence of CR-BSI and VT. However, catheter site bleeding
complications are higher and warrants further investigation.
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CRYOTHERAPY (ICE CHIPS) IS EFFECTIVE IN PREVENTING MELPHA-
LAN-INDUCED ORAL MUCOSITIS (OM) IN PATIENTS WITH AL AMY-
LOIDOSIS
Finn, K.T., Sanchorawala, V., Kunz, R., Seldin, D., Wilkes, G., Oran,
B. Boston Medical Center, Boston, MA
OM is a frequent complication following high dose melphalan
chemotherapy due to its cytocidal effect on normal, rapidly divid-
ing cells in the oral mucosa. Unfortunately, OM commonly pre-
cedes or occurs at the same time as chemotherapy-induced myelo-
suppression, placing patients at high risk for systemic infection,
longer hospital admissions, malnutrition, poor quality of life and
increased morbidity and mortality. In order to identify incidence of
OM and protection from cryotherapy, a retrospective analysis was
conducted at BMC to identify the incidence of OM as deﬁned by
SWOG criteria grade 2 or (moderate, severe or life-threatening)
in 179 patients with AL amyloidosis who received Melphalan
200mg/m2 in 2 divided doses over 2 days, followed by stem cell
rescue. 25 patients received cryotherapy (entire mouths cooled
using ice chips) 10 minutes before, all during and for 10 minutes
after melphalan infusion and 154 patients did not receive cryother-
apy. All patients followed the same mouth care regimen beginning
the ﬁrst day of melphalan (baking soda, antibacterial mouth rinses,
nystatin swish and swallow). Patients without cryotherapy treat-
ment were 10 times more likely (OR  10, 95% CI  2.59-38.46,
p  0.001) to develop OM (n  94) than those that did receive
cryotherapy (n  4). We found no difference in incidence of OM
if stem cells were infused between 24-48 hours after melphalan
(P  0.33) but found that patients were 6.25 times more likely
(95% CI 1.31-29.75, p 0.02) to develop OM if stem cells were
infused 72 hours later. Patients with pre-treatment creatinine levels
between 1.20-1.99mg/dl were 2.56 times more likely (95% CI 
1.11-5.93, p 0.03) and patients with creatinine 2.0 mg/dl were
5.79 times more likely (95% CI  1.08-31.07, p  0.04) and
patients on hemodialysis were 5.96 times more likely (95% CI 
1.01-35.57, p  0.05) to develop OM as compared to those with
normal creatinine levels. Patients who experienced vomiting were
3.11 times more likely (95% CI  1.53-6.33, p  0.002) to develop
OM. Oral cryotherapy is effective in reducing the incidence of OM
resulting from high dose melphalan in patients with AL amyloidosis.
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ROLE OF LOW-DOSE HEPARIN, URSODIOL AND GLUTAMINE IN PRE-
VENTING VENO-OCCLUSSIVE DISEASE OF THE LIVER IN ADULTS UN-
DERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Desai, M.R., McCreary, E.L., Focazio, B., Devoe, C., John, V.S., Bayer,
R.-L. North Shore University Hospital, NYU School of Medicine,
Manhasset, NY
The clinical syndrome of veno-occlusive disease (VOD) of the
liver after hematopoeitic stem cell transplant (HSCT) is charac-
terized by jaundice, painful hepatomegaly and ﬂuid retention with
weight gain. Cytoreductive chemotherapy is felt to be the primary
cause of VOD, along with other risk factors. The incidence of
VOD in adults undergoing HSCT ranges between 25% to 65%.
VOD is considered to be the third leading cause of mortality (3%
to 67%) after GVHD and infection in HSCT patients. The patho-
physiology of VOD is not clear but the underlying mechanism is
felt to be due to high dose chemotherapy causing endothelial injury
of the sinusoids and small hepatic venules. This endothelial injury
induces a local hypercoagulable state by activating the coagulation
cascade and favoring clot formation. Fibrin related aggregates and
entrapment of ﬂuid and cellular debris occlude the small pores that
perforate the endothelial lining. This causes hepatic venous out-
ﬂow obstruction that generates a post sinusoidal intrahepatic portal
hypertension which is responsible for the clinical features of VOD.
Low dose heparin has been used as an anticoagulant in the pro-
phylaxis of VOD. Ursodiol, a hydrophilic nonhepatotoxic bile salt,
may be beneﬁcial in VOD prevention as it may replace more toxic
bile salts preventing damage by cholestasis. Glutathione (GSH), a
biosynthetic derivative of glutamine, is depleted during chemo-
therapy. Supplemental glutamine has been shown to preserve GSH
concentration thereby preventing hepatocellular damage seen in
VOD. Based on this information, we conducted a retrospective
study looking at 92 patients in our institution from January 2002 to
present who were treated with low dose heparin infusion (100
units/kg/day), ursodiol (300 mg po bid), and glutamine (7.5 gms po
bid). This regimen was started on the day of admission and dis-
continued prior to discharge. We reviewed the signs and symptoms
of VOD using the Seattle criteria. Hepatic doppler was obtained to
document reversal of ﬂow in hepatic and portal venous circulation.
The patient characteristics are shown in the table below. Out of 92
patients, 2 (2%) developed signs and symptoms consistent with
VOD with negative color doppler studies. Both of the patients
received allogeneic sibling transplants. Our experience demon-
strates a relatively low incidence of VOD in HSCT patients with
the above prophylactic regimen and we recommend its use.
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CLINICAL EVALUATION OF THE ADVERSE EFFECTS OF VORICONAZOLE
IN THE MANAGEMENT OF HEMOPOEITIC STEM CELL TRANSPLANT
PATIENTS
Li, H., Mazj, S., John, V., Focazio, B., Devoe, C., Bayer, R.-L. North
Shore University Hospital, NYU School of Medicine, Manhasset, NY
Fungal infection is one of the most important causes of morbidity
and mortality in hemopoeitic stem cell transplant (HSCT) recip-
ients. The growing incidence of fungal infection is related to
several factors including prolonged granulocytopenia, use of
broad-spectrum antibiotics, conditioning regimens, and use of im-
munosuppression to avoid graft-versus-host disease. Amphotericin
B with or without 5-ﬂucytosine is considered the standard therapy
for acute candidiasis with ﬂuconazole as an alternative. Amphoter-
icin B is also the ﬁrst-line therapy for invasive aspergillosis in
neutropenic patients. However nephrotoxicity is a major side effect
of amphothericin B, particularly in patients with HSCT needing
cyclosporine concurrently with amphotericin B. Both of these
drugs are nephrotoxic and impaired renal function may be ob-
served. Even with the development of the liposomal formulations
of amphotericin B, there is still about a 20% risk of nephrotoxicity.
Possible liposomal amphotericin B-induced nephrogenic diabetes
insipidus has also been reported. Third generation triazoles have
become available and have broadened the spectrum of effects
against invasive aspergillosis. The efﬁcacy of voriconazole (VRC)
in the treatment of invasive aspergillosis in patients with acute
myeloid leukemia undergoing HSCT has been reported. However
there is no report regarding the adverse effects of VRC in the
management of HSCT patients (PubMed Jan. 2001-Oct. 2003).
Therefore we conducted this retrospective study to assess the
adverse effects of VRC in HSCT patients (Jan. 2002 to Oct. 2003)
and to evaluate the safety of the empiric use of VRC in HSCT
patients. A total of 31 patients post HSCT received VRC. The
characteristics of the patients are shown in table.1. All adverse
events and laboratory abnormalities during treatment and follow-up
Table. Patient Characteristics
Age Median 48 years Range 22-66 years
Sex/(N) 92 Male 57 Female 35
Diagnosis Leukemia/lymphoma
38/27
Multiple myeloma/
solid tumors 25/2
Type of transplant Autologous 77 Allogeneic 15
Conditioning
regimen
Chemotherapy with total
body irradiation 9
Chemotherapy 83
MDS, myelodysplastic syndrome.
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were recorded and their relationship to VRC was determined. There
were two patients with mild elevation in liver function tests not
necessitating discontinuation of VRCwith spontaneous normalization
of liver function tests while on VRC. There was one patient with
confusion, noted three days after the initiation of VRC while on
narcotics. The confusion resolved upon discontinuing VRC and
adjusting narcotics. VRC was not restarted due to resolution of
fever and engraftment. Unlike prior reports we did not observe any
skin rashes or visual disturbances. Our experience conﬁrms the
safety and tolerability of VRC in HSCT patients.
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OPEN-LABEL, RANDOMIZED COMPARISON OF DOLASETRON VERSUS
ONDANSETRON FOR PREVENTION OF NAUSEA AND VOMITING DUR-
ING HIGH-DOSE CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
Mandanas, R.A.1, Beveridge, R.A.2, Rifkin, R.M.3, Wallace, H.J.4,
Greenspan, A.5, Spitzer, G.6, Guo, H.7, Asmar, L.7 1. Cancer Care
Associates, Oklahoma City, OK; 2. Fairfax-Northern Virginia Hema-
tology-Oncology, Fairfax, VA; 3. Rocky Mountain Cancer Centers, Den-
ver, CO; 4. Piedmont Hematology-Oncology Associates, Winston-Salem,
NC; 5. Central Indiana Cancer Centers, Indianapolis, IN; 6. Cancer
Centers of the Carolinas, Greenville, SC; 7. US Oncology, Houston, TX
5-HT3 antagonists are now the standard for the prevention of
nausea and vomiting during conventional dose highly emetogenic
chemotherapy. Little data are available for the routine use of these
agents in the high-dose chemotherapy (HDC) and transplant set-
tings. Between May 1997 and March 2001, 197 patients were
randomized to received either Dolasetron (D) at 100 mg IV and
100 mg PO 8-12 hours later or Ondansetron (O) at 32 mg IV and
8 mg PO 8-12 hours later during HDC regimens for breast cancer
(STAMP V, n  96, 48.7%), non-Hodgkin’s lymphoma (BEAC,
n  83, 42.1%), and Hodgkin’s disease (CBV, n  18, 9.1%). In
addition to the 5-HT3 antagonist all patients also received dexa-
methasone 10 mg IV daily and an antiemetic pump containing
benadryl, lorazepam and dexamethasone (BAD) delivered at a con-
tinuous rate with patient-controlled on-demand bolus doses as
needed. Results: 164 (83 in D, 81 in O) of 197 patients were
evaluable after completing a daily diary which also included a visual
assessment scoring (VAS) for degree of nausea. Complete response
(no vomiting episode and no use of rescue medications) occurred in
D  36.1% and O  39.5%; major response (1 or 2 episodes of
vomiting with no rescue medications) in D  26.5% and O 
25.9%; and treatment failure (2 or more episodes in a 24 hour
period not relieved by BAD boluses or use of or request for rescue
medications) in D  23% and O  22%; all comparisons not
showing any signiﬁcant differences (p  0.5910). More than 70%
of patients in each arm showed varying degrees of nausea by VAS
scale. Subgroup analyses also failed to show any statistical differ-
ence in responses and failures between D and O when used for any
particular HDC regimen studied. Conclusion: D and O at the
doses studied are equivalent in responses and failures for the
prevention of nausea and vomiting in HDC and stem cell trans-
plantation. More than 70% of patients at least achieve good control
of vomiting with these agents in combination with dexamethasone
and an antiemetic (BAD) infusion pump.
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ROLE OF MUSIC THERAPY-BASED RELAXATION VS. EXPRESSIVE READ-
ING INTERVENTIONS IN BLOOD MARROW STEM CELL TRANSPLANTA-
TION
Liesveld, J.L.1, Sahler, O.J.Z.1, Hunter, B.C.2, Huang, L.-S.1, Oliva,
R.1 1. University of Rochester, Rochester, NY; 2. Nazareth College,
Rochester, NY
Patients undergoing hematopoietic stem cell transplantation of-
ten experience signiﬁcant pain, nausea, or emesis despite prophy-
lactic and therapeutic pharmacologic interventions. A randomized
controlled pilot study at the University of Rochester has been
conducted to determine the effects of a music therapy-based re-
laxation/stress reduction intervention, compared to an active con-
trol condition (expressive reading), on side effects related to
chemo-or radiotherapy and to determine whether any positive or
negative effects on graft or immune reconstitution were inﬂuenced
by these interventions. A total of 96 patients were accrued to the
study; 32 received music therapy, 33 expressive reading, and 31 no
intervention beyond usual supportive care. There were no signif-
icant differences in demographic or baseline variables among the
groups. The music therapy group received an average of 5.59
intervention seessions (range 1-11) and the expresive reading
group 6.06 (1-17) (NS) during their inpatient stays. Neither the
intervention nor the number of intervention sessions received
affected average number of days to engraftment or days to dis-
charge. However, both the music therapy and expressive reading
interventions resulted in a signiﬁcant reduction in pain and nausea
based on a visual analog scale administered before and after each
session. On Day 7 of transplant, those patients receiving music
therapy had a decrease in patient-requested medication as com-
pared to controls (1.22 vs. 4.27), but there was no signiﬁcant
difference between intervention groups in p.r.n. analgesic admin-
istration. No signiﬁcant difference among groups was found for
frequency of emesis. The relaxation intervention given was not
associated with differences in the levels of selected cytokines (IL-
1a, TNF-a, or interleukin-6) or in absolute lymphocyte counts at
Day 100. This pilot study demonstrates the feasibiltiy of relax-
ation interventions in a stem cell transplant population and begins
to discern possible areas of impact. Further controlled studies are
required to determine (1) whether any speciﬁc effects accrue to
music therapy interventions as compared with other relaxation
interventions, and (2) the role of time and attention, regardless of
speciﬁc activity, on immediate symptom relief.
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DETECTION AND VIRAL LOAD MONITORING OF BK VIRUS IN HEMOR-
RHAGIC CYSTITIS COMPLICATING BONE MARROW TRANSPLANT PA-
TIENTS
Manna, P.1, Wall, D.2, Grimely, M.2, Arnoldi, S.1, Vats, A.3 1.
ViraCor Laboratories, Lee’s Summit, MO; 2. Texas Transplant Insti-
tute/Southwest Texas Methodist Children’s Hospital, San Antonio, TX;
3. Children’s Hospital of Pittsburgh, Pittsburgh, PA
Introduction: Hemorrhagic cystitis causes signiﬁcant morbidity
and mortality in bone marrow transplant (BMT) patients. Recent
reports suggest the association of BK virus (BKV) in BMT patients
with hemorrhagic cystitis due to reactivation of BKV under im-
munosuppressive conditions. Thus, management of serious BKV
Table.
Number of patients 31
Mean age (range) 48 (25-65)
Sex Male 24 (77%), Female 7 (23%)
Underlying disease AML 11 (36%), NHL 7 (22%),
HD 4 (13%), MM 4 (13%), ALL
3 (10%), CML 1 (3%), Germ
cell 1 (3%)
Type of HSCT Auto 28 (90%), Allo 3 (10%)
Mean days of neutropeina
(range)
19 (7-57)
Route of VRC administration PO 15 (49%), IV 10 (32%),
IVPO 6 (19%)
Dose of VRC 400mg q12hr for two doses
then 200mg q 12hr
Mean days of VRC
administration (range)
13 (2-45)
Adverse effects Elevation of LFT’s 2 (6%),
Confusion 1 (3%)
HSCT, hemopoietc stem cell transplant; VRC, voriconazole; AMI,
acute myeloid leukemia; CML, chronic myeloid leukemia;
ALL, acute lymphoid leukemia; MM, multiple myeloma; HD,
Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; LFT,
liver function test.
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